Document is current
Any future updates will be listed below
-
Authors
Imaizumi, Yoshitaka https://orcid.org/0000-0002-2954-5691
Iwanaga, Masako
Nosaka, Kisato
Ishitsuka, Kenji
Ishizawa, Kenichi
Ito, Shigeki
Amano, Masahiro
Ishida, Takashi
Uike, Naokuni
Utsunomiya, Atae
Ohshima, Koichi
Tanaka, Junji
Tokura, Yoshiki
Tobinai, Kensei
Watanabe, Toshiki
Uchimaru, Kaoru
Tsukasaki, Kunihiro
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H23-GanRinsho-Ippan-020, the Ministry of Health, Labor, Welfare of Japan)
Japan Agency for Medical Research and Development (Japan Agency for Medical Research, Development, 18ck0106338s0502)
- License Information
-
More Information
Article History
Received: 19 July 2022
Revised: 7 October 2022
Accepted: 11 October 2022
First Online: 29 October 2022
Declarations
:
: Kisato Nosaka reports consulting fees from Kyowa Kirin and honoraria from Celgene, Meiji Seka Pharma, Janssen Pharmaceutical, Bristol Myers Squbb, Abbie, Daiichi Sankyo, and Novartis. Kenji Ishitsuka reports grants from Ono Pharmaceutical and Kyowa Kirin, consulting fees from Daiichi-Sankyo, and honoraria from Chugai Pharmaceutical and Meiji Seika Pharma. Kenichi Ishizawa reports grants from SymBio, IQVIA, Novartis, Abbie, Zenyaku, and Otsuka Pharmaceutical, consulting fees from SAWAI, Micron, and Kyowa Kirin, and honoraria from Novartis, Takeda, Bristol Myers Squbb, Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, and Janssen Pharmaceutical. Atae Utsunomiya reports consulting fees from JIMRO and Otsuka Medical Devices and honoraria from Bristol Myers Squbb and Meiji Seka Pharma. Koichi Oshima reports honoraria from Chugai Pharmaceutical, Kyowa Kirin, and Takeda. Kuhnihiro Tsukasaki reports consulting fees from Ono Pharmaceutical, Meiji Seka Pharma, Yakuruto, Solasia Pharma, Meiji Seika Pharma, and HUYABIO, honoraria from Chugai Pharmaceutical, Eizai, and Meiji Seika Pharma, and research funding from Kyowa Kirin, Meiji Seika Pharma, Celgene, Byer, Daiich-Sankyo, HUYABIO, and Regeneron Pharmaceuticals. All remaining authors have no conflicts of interest to declare.
